[1] Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway[J]. Journal of Cell Science, 2004, 117(8):1281-1283. [2] Krebs DL, Hilton DJ. SOCS proteins:negative regulators of cytokine signaling[J]. Stem Cells, 2001, 19(5):378-387. [3] Sham P, Bader JS, Craig I, et al. DNA pooling:a tool for large-scale association studies[J]. Nature Reviews Genetics, 2002, 3(11):862-871. [4] Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas[J]. Journal of the National Cancer Institute, 2000, 92(7):569-573. [5] Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors[J]. Cell, 1998, 93(3):385-395. [6] Jin H, Lanning NJ, Carter-Su C. JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells[J]. Mol Endocrinol, 2008, 22(8):1825-1841. [7] Deng L, Jiang J, Frank SJ. Growth hormone-induced JAK2 signaling and GH receptor down-regulation:role of GH receptor intracellular domain tyrosine residues[J]. Endocrinology, 2012, 153(5):2311-2322. [8] Kiu H, Nicholson S. Biology and significance of the JAK/STAT signalling pathways[J]. Growth Factors, 2012, 30(2):88-106. [9] Putters J, da Silva Almeida AC, van Kerkhof P, et al. Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor[J]. PLoS One, 2011, 6(2):e14676. [10] He K, Loesch K, Cowan JW, et al. Janus kinase 2 enhances the stability of the mature growth hormone receptor[J]. Endocrinology, 2005, 146(11):4755-4765. [11] Hu K, Hou S, Jiang Z, et al. JAK2 and STAT3 polymorphisms in a Han Chinese Population with Behcet’s disease[J]. Investigative Ophthalmology & Visual Science, 2012, 53(1):538-541. [12] Liu W, Sun D, Yu Y, et al. Association of Janus kinase 2 polymorp-hisms with growth and reproduction traits in chickens[J]. Poultry Science, 2010, 89(12):2573-2579. |